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Abstract. Inflammation appears to be the cause of aortic 
valve (AoV) stenosis and identification of predictive 
biomarkers is therefore imperative. The aim of the current 
study was to evaluate the potential role of  serum chemerin 
and fibroblast growth factor-21 (FGF-21) in the pathogenesis 
of the disease. A total of 102 patients were selected based on 
certain criteria and divided into an aortic stenosis group and 
a control group. Patients with AoV stenosis were subdivided 
into three groups depending on the severity according to 
the echocardiography criteria: Aortic jet velocity, Vmax (m/
sec); mean pressure gradient, PG (mmHg); aortic valve area 
(AVA), cm2; and indexed AVA, cm2/m2. Patients were graded 
as: Severe: Vmax >4 m/sec, PG >40 mmHg, AVA <1.0 cm2, 
indexed AVA <0.6; moderate: Vmax 3.0-4.0 m/sec, PG 
20-40 mmHg, AVA 1.0-1.5 cm2, indexed AVA 0.60-0.85; mild: 
Vmax 2.5-2.9 m/sec, PG <20 mmHg, AVA >1.5 cm2, indexed 
AVA >0.85. ELISA was used for the detection of chemerin 
and FGF-21. Post-hoc analysis with Tukey's correction was 
performed. The highest chemerin levels were found in mild 
and moderate AoV stenosis and decreased along with the 
grade of severity, compared with the control group. The 
FGF-21 level was increased in all the stenosis groups, reaching 
the highest level at severe stenosis. Receiver-operating 
characteristic analysis of chemerin in all the AoV stenosis 
groups without grading the severity included, area under the 
curve (AUC)=0.76; 0.70-0.80= fair; P<0.001 and for mild 
AoV stenosis was AUC=0.82; 0.80-0.90= good; P<0.001. In 
conclusion, chemerin is a good diagnostic biomarker for mild 
AoV stenosis, while FGF-21 is a moderate diagnostic marker.
Introduction
Aortic valve stenosis (AoV), a global cardiovascular health 
concern, is the most frequent valve disease, the third most 
frequent cardiovascular disease after arterial hypertension 
and coronary heart disease, and the most widespread indica-
tion for surgical valve replacement (1-3). Data of systemic 
studies showed that calcific AoV sclerosis is present in 
approximately 9% of patients aged 54 and above, to 42% at 
age 81. In 1.8-1.9% of patients, AoV sclerosis progresses to 
clinical calcific AoV stenosis. These patients have increased 
risk of coronary heart disease (68%), myocardial infarction 
(27%), cardiac death (69%), and risk of other etiology death, 
which makes calcific AoV stenosis a significant risk factor 
for morbidity and mortality in the age groups mentioned (4). 
If the AoV is not replaced, 75% of patients succumb in 
3 years and 50% above the age of 65 years succumb within 
2 years after the occurrence of symptoms such as chest pain, 
syncope, and heart failure (5). Historically, AoV stenosis 
was considered a degenerative disease related to aging, and 
wear and tear of the valve. Nevertheless, there is no distinct 
answer as to whether it is the cause of AoV stenosis onset and 
progression, as many elderly people do not suffer from this 
disease (6).
Regarding pathogenetic aspects of AoV stenosis, valves 
are made of specialized cells with distinct functions: 
Valvular endothelial cells, valvular interstitial cells, and the 
extracellular matrix, which consists of collagen, elastin, and 
glycosaminoglycans. Valvular interstitial cells are of five 
different phenotypes with distinct biological functions; embry-
onic endothelial and mesenchymal progenitor cells, quiescent, 
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activated, progenitor, and osteoblast-like valvular interstitial 
cells, with the latter contributing to the calcification of AoV (1).
Calcification at the tissue level is the most common finding 
in AoV stenosis (7). There are findings to prove the active 
inflammation process, such as the increased expression of 
C-reactive protein (CRP), increased temperature in stenotic 
valve leaflets, and a special non-invasive method combining 
positron emission tomography and computed tomography 
using a ligand 18 fluordesoxyglucose, therefore proving the 
activity of macrophages in stenotic valve leaflets (8,9).
Chemerin is an adipokine known as a ligand for G protein- 
coupled chemokine-like receptor 1, also known as chemerin 
receptor 23, which was first identified in macrophages and 
dendritic cells (10-12). The main source of chemerin is white 
adipose tissue, but a high concentration was also found in the 
liver (13,14), lower lungs, brown adipose tissue, heart, ovaries, 
kidneys, skeletal muscle, and pancreas (15). The circulating 
chemerin level strongly correlates with the level of inflamma-
tory markers such as tumor necrosis factor (TNF)-α, interleukin 
(IL)-6, high-sensitivity CRP, resistin, and leptin (15,16) in 
humans and animals (17-19). Chemerin regulates the inflam-
matory process by promoting the migration of macrophages to 
certain tissues such as adipose tissue (20).
It is clear that chemerin has a role in inflammatory 
processes, but there is still no consensus whether it is a pro- 
or anti-inflammatory activity (21-27). Eisinger et al showed 
that chemerin has no positive correlation with the severity of 
inflammation (17). A link between the severity grade of liver 
cirrhosis and the severity of chronic hepatitis C and plasma 
chemerin levels has been investigated, and a negative correla-
tion was found in both cases, which leads to the conclusion 
that chemerin may have a protective role in the inflammation 
process (17,28). Studies revealed that various chemerin frag-
ments with pro- and anti-inflammatory activity are produced 
depending on predominating proteases in the inflammatory 
process (29,30).
Fibroblast growth factor-21 (FGF-21) has an important role 
in cardiovascular diseases. It is a protein secreted in the liver, 
skeletal muscle, adipose tissue, and pancreas (31). It has been 
found that the FGF-21 serum level is increased in patients with 
abnormal lipid profiles, obesity, metabolic syndrome, reduced 
glucose tolerance, diabetes type 2, hypertension, non-alco-
holic fatty liver disease, and coronary artery disease (31-33). 
Similarly, the FGF-21 level is increased in patients with coro-
nary heart disease and atherosclerotic plaques of the carotid 
arteries; thus, FGF-21 can be used as a biomarker in athero-
sclerotic diseases (34-36).
FGF-21 has been shown to reduce IL-6, IL-β, and TNF-α 
production, which assume the main role in the pathogenesis of 
inflammation (37).
Findings support the protective role of FGF-21's in different 
cardiovascular diseases, such as atrial fibrillation, myocardial 
infarction, coronary artery disease, and hypertension. Han et al 
stated that the FGF-21 level was markedly higher in patients 
with atrial fibrillation compared to a control group (38).
It is also stated that cardiomyocytes are capable of secreting 
FGF-21 as a response to various stress factors, such as cardiac 
hypertrophy or myocardial infarction (39-42). FGF-21 has an 
autocrine effect on preventing cardiac inflammation, develop-
ment of hypertrophy, apoptosis of cardiomyocytes, and the 
emergence of oxygen-free radicals, as well as promoting the 
oxidation of fatty acids (42).
The aim of the present study was to evaluate serum 
chemerin and serum FGF-21 as possible biomarkers of AoV 
stenosis and to study inflammation in the pathogenesis of AoV 
stenosis.
Patients and methods
Study population. This prospective study was conducted 
from 2013 to 2016 in different hospitals in Latvia. The study 
protocol had prior approval from the Riga Stradins University 
(Riga, Latvia) Ethics Committee on research on humans and 
the study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki.
A total of 102 patients were selected on the basis of inclusion 
and exclusion criteria and divided in two core groups, a control 
and an AoV stenosis group. The control group included patients 
without AoV stenosis aged from 55 to 80 years, which complies 
with the average age of AoV stenosis patients according to the 
Guidelines on the Management of Valvular Heart Disease 
2012 of the European Society of Cardiology (43). Written 
informed consent was obtained from each patient included in 
the study. Patients were included in the control group according 
to echocardiographically confirmed results of a healthy AoV. 
Exclusion criteria in the two groups were obesity, systemic 
connective tissue, infectious and oncological diseases, diabetes, 
thyroid dysfunction and arterial hypertension, atherosclerotic 
coronary artery disease, heart failure, myocardial infarction, 
cerebral infarction and transient ischemic attack. Exclusion 
criteria in AoV stenosis group were patients with congenital 
AoV stenosis and rheumatic AoV stenosis.
AoV stenosis assessment. Patients were examined echocardio-
graphically and the data were archived using GE VIVID 
7 Dimension and Philips IE 33, both from KPI Healthcare 
(Yorba Linda, CA, USA). Each echocardiography examination 
was evaluated by two professionals.
Patients with AoV stenosis were subdivided into three 
groups (Table I) depending on the severity grade according 
to the echocardiography criteria: aortic jet velocity (Vmax) 
(m/sec); mean pressure gradient, PG (mmHg); aortic valve 
area, AVA (cm2) and indexed AVA (cm2/m2). Data were graded 
as: Severe: Vmax >4 m/sec, PG >40 mmHg, AVA <1.0 cm2, 
indexed AVA <0.6; moderate: Vmax 3.0-4.0 m/sec, PG 
20-40 mmHg, AVA 1.0-1.5 cm2, indexed AVA 0.60-0.85; mild: 
Vmax 2.5-2.9 m/sec, PG <20 mmHg, AVA >1.5 cm2, indexed 
AVA >0.85.
Biochemical analysis. Venous blood samples were taken and 
serum was obtained in accordance with the serum preparation 
instructions. Serum samples were stored at -80˚C and were 
available in 102 patients. We obtained laboratory analyses 
for all the patients at the Biochemistry Laboratory of the 
Riga Stradins University, including chemerin and FGF-21 
with the ELISA method, using human Chemerin ELISA 
(cat. no. EZHCMRN-57K) and human FGF-21 ELISA (cat. 
no. EZHFGF21-19K) kits, both produced by EMD Millipore 
(Billerica, MA, USA). Results were detected using a TECAN 
Infinite 200 PRO multimode reader (Tecan Group, Ltd., 
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Mannedorf, Switzerland) . The procedure was carried out in 
accordance with the manufacturer's instructions.
Statistical analysis. The data were analyzed using IBM SPSS 
version 23.0 (IBM Corp., Armonk, NY, USA). Descriptive 
statistics were performed according to the data type. The 
results for age, body mass index, low-density lipoprotein 
cholesterol, total cholesterol, triglycerides and ejection frac-
tion, as well as stroke volume are expressed as mean (M) and 
standard deviation (± SD). Results for high-sensitivity CRP are 
expressed as median and interquartile range.
Laboratory parameters between the groups were compared 
using analysis of covariance (ANCOVA) while controlling 
age as a covariate. Tukey's test was used as a post-hoc test to 
determine any significant differences between the groups. The 
performance of the chemerin and FGF-21 was assessed using 
receiver-operating characteristic (ROC) curves, sensitivity, 
specificity, and negative and positive predictive values. The 
P-value was reported for the area under the curve (AUC) for the 
best cut-off level. Diagnostic tests were assessed by this clas-
sification: 0.90-1=excellent; 0.80-0.90=good; 0.70-0.80=fair; 
0.60-0.70=poor; and 0.50-0.60=fail. A two-tailed P-value less 
than 0.05 was considered to indicate a statistically significant 
difference.
Results
Patient characteristics. Patient characteristics are provided in 
Table I and the results of laboratory measurements in Tables II 
and III. A total of 102 patients were included and divided into 
Table I. Baseline characteristics of the patients.
 Control  AoV mild stenosis AoV moderate stenosis AoV severe stenosis
Characteristics n=50 n=18 n=19 n=15
Sex (%)    
  Male 11 (22.0) 2 (11.1) 8 (42.1) 7 (46.7)
  Female  39 (78.0) 16 (88.9) 11 (57.9) 8 (53.3)
Age, mean ± SD 65.18 (9.74) 70.53 (6.08) 72.16 (8.20) 65.27 (8.13)
P-value vs. control  P=0.127 P=0.012 P>0.999
BMIa, mean ± SD 26.04 (4.31) 27.39 (3.10) 25.81 (4.58) 27.40 (3.18)
P-value vs. control  P=0.399 P=0.682 P=0.869
LDLb, mmol/l mean ± SD 3.28 (1.18) 3.05 (0.97) 2.59 (0.92) 3.10 (1.12)
P-value vs. control  P>0.999 P=0.057 P>0.999
Triglycerides mmol/l, mean ± SD 1.47 (0.71) 1.64 (0.84) 1.11 (0.56) 1.27 (0.57)
P-value vs. control  P=0.406 P=0.178 P=0.406
Total cholesterol mmol/l, mean ± SD 5.49 (1.28) 5.01 (1.34) 4.21 (1.18) 4.68 (1.08)
P-value vs. control  P=0.056 P=0.001 P=0.016
hs-CRPc mg/l,  5.03 4.69  5.27 3.7
Median (IQR) (2.12-14.23) (3.42-7.35) (1.71-11.14) (1.56-11.9)
P-value vs. control  P>0.999 P>0.999 P>0.999
dSV ml, mean ± SD 81.86 (20.11) 73.63 (18.92) 77.72 (18.65) 75.93 (15.49)
P-value vs. control  P=0,299 P=0.501 P=0.501
eEF %, mean ± SD 62.22 (6.35) 57.16 (9.23) 61.78 (8.23) 56.13 (7.84)
P-value vs. control  P=0.014 P=0.291 P=0.007
aBMI, weight in kilograms divided by the square of the height in meters; bLDL, low-density lipoprotein cholesterol; hs-CRPc, is high-sensitivity 
C-reactive protein; dSV, stroke volume, measured by left ventricular outflow method; eEF, ejection fraction, measured by Simpson's method. 
Bold, statistically significant.
Table II. Sensitivity and specificity of the chemerin and FGF-21 in patients with aortic valve stenosis (including all severity 
degrees of stenosis).
Biomarker AUC (95% CI) P-value Cut-off value Sp % Se % NPV % PPV % Accuracy %
Chemerin (ng/ml) 0.76 (0.67-0.85) <0.001 38.60 55 80 72.2 63.6 67.5
FGF (pg/ml) 0.67 (0.56-0.77) 0.003 309.83 67 61.5 61.5 66.6 64.2
AUC, area under the curve; Sp, specificity; Se, sensitivity; NPV, negative predictive value; PPV, positive predictive value; FGF, fibroblast 
growth factor.
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three AoV stenosis severity groups and a control group: A 
total of 18 patients had mild, 19 moderate, and 15 severe AoV 
stenosis, and there were 50 patients in the control group. The 
average age of the patients in the aortic stenosis groups and the 
control group were similar, and the mean level of body mass 
index did not differ between the groups.
Chemerin and FGF-21 level differences between the patient 
groups. A box and whisker plot of chemerin and FGF-21 
for the control and AoV stenosis groups is shown in Fig. 1. 
The mean chemerin and FGF-21 levels had a statistically 
significant difference in the study groups (ANCOVA, P<0.001, 
and P=0.03; age as covariate). To evaluate a difference 
between the groups, a post-hoc analysis with Tukey's 
correction for chemerin was performed. Results showed that 
the control group had a statistically significant difference with 
the mild AoV stenosis group (P<0.001), with the moderate 
AoV stenosis group (P=0.005), and with the severe AoV 
stenosis group (P=0.04). The mild AoV stenosis group had a 
statistically significant difference with the severe AoV stenosis 
group (P<0.05), while the moderate and severe AoV stenosis 
groups had no statistically significant difference (P>0.05). 
Post-hoc analysis for FGF-21 revealed that the control group 
with moderate and severe stenosis groups had a statistically 
Figure 1. Box and whisker plot of chemerin and FGF-21 in the control and 
AoV stenosis groups. The highest plasma chemerin level was found in mild 
AoV stenosis. The highest plasma FGF-21 level was found in severe AoV 
stenosis. FGF-21, fibroblast growth factor-21; AoV, aortic valve.
Figure 2. ROC analysis of chemerin and FGF-21 as diagnostic markers 
of AoV stenosis in the control group vs. all stenosis groups. Chemerin: 
AUC=0.76 and precision category, fair, a moderate diagnostic biomarker 
for AoV stenosis; FGF-21: AUC=0.67 and precision category, poor, weak, 
biomarker for AoV stenosis. AUC, area under the curve; ROC, receiver-opera 
ting characteristic; FGF-21, fibroblast growth factor-21.
Figure 3. ROC analysis of chemerin and FGF-21 as diagnostic markers of 
the AoV stenosis - control group vs. the mild AoV stenosis group. Chemerin: 
AUC=0.82 and precision category, good, a good diagnostic biomarker for 
AoV stenosis; FGF-21: AUC=0.66 and precision category, poor, weak, bio-
marker for AoV stenosis. AUC, area under the curve; ROC, receiver-opera 
ting characteristic; FGF-21, fibroblast growth factor-21
Table III. Sensitivity and specificity of chemerin and FGF-21 in the mild AoV stenosis group.
Biomarker AUC (95% CI) P-value Cut-off value Sp % Se % NPV % PPV % Accuracy %
Chemerin (ng/ml) 0.82 (0.70-0.95) <0.001 43.12 69 87 75.5 71.9 78
FGF (pg/ml) 0.66 (0.51-0.81) 0.04 283.78 61 75 64.4 65.4 68
AUC, area under the curve; Sp, specificity; Se, sensitivity; NPV, negative predictive value; PPV, positive predictive value; FGF-21, fibroblast 
growth factor-21; CI, confidence interval; AoV, aortic valve.
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significant difference (P<0.05), but for the rest of the groups, 
there was no statistically significant difference (P>0.05) 
(Fig. 1).
The chemerin serum level increased in all three stenosis 
groups. The highest chemerin levels were found in mild and 
moderate AoV stenosis and decreased along with the grade of 
severity, compared to the control group (Fig. 1). The FGF-21 
level increased in all of the stenosis groups, but the FGF-21 
level in serum increased along with the AoV stenosis severity 
grade, reaching the maximum for severe stenosis (Fig. 1).
Predictive values of chemerin as biomarker. The ROC analysis 
showed that chemerin is a moderate diagnostic marker in all 
AoV stenosis groups without grading the severity (AUC =0.76; 
0.70-0.80=fair; P<0.001) (Fig. 2 and Table II). At the same 
time, the ROC curve shows that chemerin is a specific and 
sensitive biomarker for mild AoV stenosis (AUC= 0.82; 
0.80-0.90=good; P<0.001) (Fig. 3 and Table III). The optimal 
cut-off value for chemerin in the ROC curve was 43.12 ng/ml 
at Se=87%, Sp=69%. FGF-21 is a poor diagnostic marker 
among all AoV stenosis groups without grading the severity 
(AUC=0.67; 0.56-0.77=poor; P=0.003) (Fig. 2 and Table II) and 
in the mild AoV stenosis group (AUC=0.66; 0.51-0.81=poor; 
P=0.04) (Fig. 3 and Table III).
Discussion
The results of the present study indicate that chemerin is a 
novel biomarker for the detection of AoV stenosis in the early 
stages, with a high sensitivity and specificity in the mild AoV 
stenosis group. Chemerin is found in different inflamma-
tory and systemic processes all over the body (13,30,44-51): 
Therefore, patients with systemic and inflammatory diseases 
were excluded from this study. Thus, in the early stages 
of AoV stenosis, an active inflammation process is domi-
nant, as chemerin is mainly considered an inflammatory 
biomarker (16,20,32) and in our study its level was the highest 
in mild AoV stenosis. There is a possibility that chemerin is 
secreted due to the activation of valvular myofibrils, although 
there is a lack of evidence to support this theory and further 
research should be conducted. In more severe stages, the serum 
chemerin level decreased, leading to the conclusion that passive 
extracellular matrix changes and calcification predominate in 
moderate and severe calcific AoV stenosis. The ROC analysis 
proves that chemerin sensitivity and specificity as a diagnostic 
biomarker in mild AoV stenosis is high; thus, this test may be 
engrained in cardiovascular risk panels for laboratory analysis. 
Early detection of AoV stenosis may improve prognosis and 
quality of life of patients, improve therapy efficiency, and help 
to avoid late compensatory complications of AoV stenosis, 
such as cardiac hypertrophy. It would be useful to study other 
biomarkers that represent the inflammation process in AoV 
stenosis and find appropriate medications for treatment. Along 
with other studies mentioned above (21-27), our study does 
not state whether chemerin has a pro- or anti-inflammatory 
role and further research should be conducted with other 
biomarkers that support varying theories.
Of note is that the FGF-21 level increases along with the 
AoV stenosis severity grade. These results have led to the 
conclusion that FGF-21 plays a protective role in calcific AoV 
stenosis pathogenesis, because in the initial stages only a 
slight increase in plasma FGF-21 was evident, but in the more 
severe grade of AoV stenosis, it significantly increased. It has 
been suggested that FGF-21 may have a cardioprotective role 
in different cardiovascular diseases such as atrial fibrillation, 
myocardial infarction, coronary artery disease, hypertension, 
and cardiac hypertrophy, which supports our findings (38,42).
In conclusion, our study indicates that chemerin is a good 
diagnostic biomarker in mild AoV stenosis and FGF-21 is a 
poor diagnostic biomarker for AoV stenosis. The present data 
show that the inflammatory process is dominant at the early 
stages of stenosis, which leads us to the conclusion that it is 
an active process not caused by atherosclerosis. Chemerin as 
a biomarker may play a clinical role if we can prove that it is 
one of the causes of inflammation; therefore, a possible treat-
ment may be found. FGF-21 undergoes a marked increase in 
severe AoV stenosis compared to healthy controls, and it may 
have a cardioprotective role. Further research is necessary to 
confirm these findings and to specify what pathogenetic role 
these markers play in AoV stenosis.
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